Therapeutics for Women's Health: Technologies and Global Markets

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,500	258 Pages	BCC Research	January, 2022	WA16894709

Best Price Guarantee
Price	from $5,500
Length	258 Pages
Publisher	BCC Research
Published Date	January, 2022
SKU	WA16894709

Therapeutics for Women's Health: Technologies and Global Markets

Report Scope:

This report is an analytical business tool that comprehensively evaluates the global market for women’s health therapeutics. The format of the study is organized around the following topics -
- Detailed study around women’s diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
- Disease incidence and prevalence.
- Regulatory structure of pharmaceutical industry.
- Market characterization, unmet need, market size and segmentation.
- Market drivers and restraints.
- Detailed market projections through 2026.
- Competition and market shares.
- Pricing and reimbursement.
- Marketed and pipeline (R&D) products along with description, regulatory status, and clinical trials.
- Observations and conclusions regarding the future of market for women’s health therapeutics.
- Profiles of market participants and associations.

Report Includes:

- 58 data tables and 56 additional tables
- An overview of the global market and technologies for women's health therapeutics
- Estimation of the market size and analyses of global market trends, with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Detailed study around women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment, etiology, pathophysiology, epidemiology, and economic burden
- Discussion on aging and women’s health disorders, women & sexual health such as female sexual arousal disorder, female orgasmic disorder, and vaginismus and relation between infertility and cancer
- Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Comprehensive company profiles of the leading players of the industry, including Roche, Eli Lilly, Pfizer, AstraZeneca, Novartis, Amgen, and Merck

Companies Mentioned

ABBVIE INC.
AMGEN INC.
ASAHI KASEI
ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB
DAIICHI SANKYO CO. LTD.
EISAI
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
MERCK KGAA
NOVARTIS AG
NOVO NORDISK
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.

Chapter 1 Introduction: Study Goals and Objectives; What's New in this Update?; Reasons for Doing This Study; Scope of Report; Information Sources; Methodology; Geographic Breakdown; Analyst's Credentials; BCC Custom Research; Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview of Technologies and Global Markets: Disease Overview and Definitions; Historical Background; Market Driving Factors and Opportunities; Aging Female Population; Government Involvement and Increased Funding; Increasing Awareness Regarding Women's Disorders and Treatments; Market Restraints; Poor Diagnosis; Availability of Alternate Treatment Options and Lifestyle Changes; Unavailability of Novel Treatments; High Treatment Cost of Osteoporosis; Opportunities; Rising Female Population in Asia-Pacific; Increased Demand for Technology Innovation; Mergers and Acquisitions
Chapter 4 Impact of COVID-19 Pandemic: Implications on Women's Health and Diagnosis; Implications on Cancer Treatment; Impact on Oncology Pharmaceuticals Market
Chapter 5 Pipeline Assessment and Analysis: Women's Health Therapeutics: Key Clinical Trial Developments; List of Drugs in Pipeline; Overview of Osteoporosis Drug Development Pipeline; Late-stage Pipeline Drugs
Chapter 6 Regulatory Structure: Overview of Regulations; U.S.; Canada; Europe; Japan
Chapter 7 Market Breakdown by Women’s Health Disorder: Introduction; Menopause-Related Diseases; Overview; Symptoms; Risk Factors; Epidemiology and Economic Burden; Diagnosis; Treatments; Market Size and Forecast; Postmenopausal Osteoporosis; Overview; Epidemiology and Economic Burden; Diagnosis; Treatments; Market Size and Forecasts; Endometriosis; Overview; Epidemiology and Economic Burden; Diagnosis; Treatments; Market Size and Forecasts; Polycystic Ovary Syndrome; Overview; Etiology; Reducing PCOS Risk; Epidemiology and Economic Burden; Disease Symptoms and Risk Factors; Diagnosis; Treatments; Market Size and Forecasts; Breast Cancer; Overview; Market Size and Forecasts
Chapter 8 Market Breakdown by Region: Introduction; North America; U.S.; Canada; Mexico; Europe; U.K.; Germany; France; Spain; Italy; Rest of Europe; Asia-Pacific; China; Japan; India; South Korea; Rest of Asia-Pacific; Rest of the World; South America; Middle East and Africa
Chapter 9 Pricing and Reimbursement: Overview of Pricing and Reimbursement; U.S.; Canada; Europe; Japan
Chapter 10 Competitive Landscape and Key Developments: Market Players and Strategies; Blockbuster Breast Cancer Pharmaceutical Brands; Patent Analysis; List of Key Patents; Key Developments; Mergers and Acquisitions; Development of Innovative Products/Novel Product Launch; Agreements, Collaborations and Partnerships; Key Products
Chapter 11 Company Profiles: ABBVIE INC.; AMGEN INC.; ASAHI KASEI; ASTRAZENECA PLC; BAYER AG; BRISTOL-MYERS SQUIBB; DAIICHI SANKYO CO. LTD.; ELI LILLY AND CO.; EISAI; F. HOFFMANN-LA ROCHE LTD.; GILEAD SCIENCES INC.; JOHNSON & JOHNSON SERVICES INC.; MERCK & CO. INC.; MERCK KGAA; NOVARTIS AG; NOVO NORDISK; PFIZER INC.; SANOFI; TAKEDA PHARMACEUTICAL CO. LTD.
Chapter 12 Conclusions: Outlook for Women’s Health Therapeutics: Major Developments to Influence Market; Therapeutic Developments; Demographic and Economic Trends; Income Growth in Emerging Markets; Future Outlook
Chapter 13 Appendix A: Glossary of Terms
Chapter 14 Appendix B: Industry and Professional Organizations
Chapter 15 Appendix C: Acronyms Used in This Report: Acronyms Used in This Report
List of Tables: Summary Table A : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026; Summary Table B : Global Market for Women’s Health Therapeutics, by Region, Through 2026; Table 1 : Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030 (Estimated); Table 2 : Recent M&A Deals in the Global Market for Women’s Health Therapeutics, 2019-2021; Table 3 : Novel Breast Cancer Drug Approvals; Table 4 : Selected New Breast Cancer Drugs in Late Stages of Clinical Development; Table 5 : Pipeline Molecules, Endometriosis; Table 6 : Pipeline Molecules, Uterine Fibroids; Table 7 : Pipeline Molecules, All Other Indications; Table 8 : Pipeline Molecules, Osteoporosis; Table 9 : Elagolix Snapshot; Table 10 : Vilaprisan Snapshot; Table 11 : Evenity Snapshot; Table 12 : Relugolix Snapshot; Table 13 : Proellex Snapshot; Table 14 : Esmya Snapshot; Table 15 : TX-004HR Snapshot; Table 16 : TX-001HR Snapshot; Table 17 : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026; Table 18 : FDA Approved Estrogen-only Medicines; Table 19 : FDA Approved Progestin-Only Medicines; Table 20 : FDA Approved Combination, Estrogen and Progestin Medicines; Table 21 : FDA Approved Combination Estrogen and Hormone Medicines; Table 22 : Vagifem (10mcg), Patent Expiration; Table 23 : Global Market for Menopause Therapeutics, by Region, Through 2026; Table 24 : Prolia/XGEVA (Denosumab) Patent Expiration; Table 25 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, Through 2026; Table 26 : Global Market for Endometriosis Therapeutics, by Region, Through 2026; Table 27 : Commonly Prescribed Generic Drugs for the Treatment of PCOS; Table 28 : Global Market for PCOS Therapeutics, by Region, Through 2026; Table 29 : TNM Classifications of Breast Cancers; Table 30 : Global Breast Cancer Incidence, 2016-2021; Table 31 : Global Breast Cancer Incidence and Mortality, by Region, 2018; Table 32 : Types of Hormone Therapy for Breast Cancer; Table 33 : Drugs Commonly Used to Treat Breast Cancer; Table 34 : Global Market for Breast Cancer Therapeutics, by Region, Through 2026; Table 35 : Global Market for Women’s Health Therapeutics, by Region, Through 2026; Table 36 : North American Market for Women’s Health Therapeutics, by Country, Through 2026; Table 37 : North American Market for Women’s Health Therapeutics, by Disease Area Through 2026; Table 38 : U.S. Market for Women’s Health Therapeutics, by Disease Area Through 2026; Table 39 : Canadian Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 40 : Mexican Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 41 : European Market for Women’s Health Therapeutics, by Country, Through 2026; Table 42 : European Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 43 : U.K. Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 44 : German Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 45 : French Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 46 : Spanish Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 47 : Italian Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 48 : Rest of the European Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 49 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 50 : RoW Market for Women’s Health Therapeutics, by Sub-region Through 2026; Table 51 : RoW Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 52 : South American Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 53 : Middle East and African Market for Women’s Health Therapeutics, by Disease Area, Through 2026; Table 54 : Blockbuster Breast Cancer Pharmaceuticals, by Company Revenue, 2018-2020; Table 55 : Major Women’s Health Therapeutics Pharmaceuticals by Company Revenue, 2020; Table 56 : Global Market Shares of Women’s Health Therapeutics, by Company Revenue, 2020; Table 57 : Patent Review, 2021; Table 58 : Novel Women’s Health Therapeutic Drug Approvals, 2021; Table 59 : Selected New Women’s Health Therapeutic Drugs in Late Stages of Clinical Development; Table 60 : Marketed Products, Postmenopausal Osteoporosis; Table 61 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020; Table 62 : AbbVie Inc.: Net Revenue, 2017–2020; Table 63 : AbbVie: Oncology Pharmaceutical Product Portfolio; Table 64 : AbbVie Inc.: Marketed Products; Table 65 : AbbVie Inc.: Key Developments, 2021; Table 66 : Allergan plc: Marketed Products; Table 67 : Allergan plc: Net Revenue, 2017-2019; Table 68 : Amgen: Oncology Pharmaceutical Product Portfolio; Table 69 : Amgen: Oncology Pharmaceutical Revenue, 2018-2020; Table 70 : Amgen: Financials, 2014–2020; Table 71 : AstraZeneca: Oncology Pharmaceutical Product Portfolio; Table 72 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020; Table 73 : Bayer AG: Marketed Products; Table 74 : Bayer AG: Oncology Pharmaceutical Product Portfolio; Table 75 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020; Table 76 : Bayer AG: Net Revenue, 2018-2020; Table 77 : Bristol-Myers Squibb: Oncology Pharmaceutical Product Portfolio; Table 78 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020; Table 79 : Daiichi Sankyo Co. Ltd.: Marketed Products; Table 80 : Daiichi Sankyo Co. Ltd.: Net Revenue 2018-2020; Table 81 : Eli Lilly and Co.: Marketed Osteoporosis Products; Table 82 : Eli Lilly and Co.: Net Revenue, 2018-2020; Table 83 : Eli Lilly and Co.: Oncology Pharmaceutical Product Portfolio; Table 84 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020; Table 85 : Roche: Oncology Pharmaceutical Product Portfolio; Table 86 : Roche: Oncology Pharmaceutical Revenue, 2018-2020; Table 87 : Gilead Sciences Inc.: Oncology Pharmaceutical Product Portfolio; Table 88 : Gilead Sciences Inc.: Oncology Pharmaceutical Revenue, 2018-2020; Table 89 : Johnson & Johnson: Oncology Pharmaceutical Product Portfolio; Table 90 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020; Table 91 : Johnson & Johnson Services Inc.: Net Revenue, 2017-2020; Table 92 : Merck & Co. Inc.: Marketed Products; Table 93 : Merck & Co. Inc.: Net Revenue, 2017–2019; Table 94 : Merck & Co. Inc.: Oncology Pharmaceutical Product Portfolio; Table 95 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020; Table 96 : Merck KGaA Marketed Products; Table 97 : Novartis: Oncology Pharmaceutical Product Portfolio; Table 98 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020; Table 99 : Novo Nordisk: Marketed Products; Table 100 : Novo Nordisk: Net Revenue, 2017–2019; Table 101 : Pfizer Inc.: Oncology Pharmaceutical Product Portfolio; Table 102 : Pfizer Inc.: Women’s Health-Marketed Products, by Indication; Table 103 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020; Table 104 : Pfizer Inc. Net Revenue, 2017–2019; Table 105 : Sanofi: Oncology Pharmaceutical Product Portfolio; Table 106 : Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020; Table 107 : Takeda Pharmaceutical Co, Ltd.: Oncology Pharmaceutical Product Portfolio; Table 108 : Takeda Pharmaceutical Co. Ltd.: Oncology Pharmaceutical Revenue, 2019-2021; Table 109 : New Cancer Cases in the U.S., by Age Group, 2018; Table 110 : Trends in Per Capita Real GDP Growth, by OECD Region, 2012-2016; Table 111 : Glossary of Terms Used in Women’s Health Therapeutics; Table 112 : Acronyms Used in Women’s Health Therapeutics
List of Figures: Summary Figure A : Global Market for Women’s Health Therapeutics, by Disease Area, 2020-2026; Summary Figure B : Global Market for Women’s Health Therapeutics, by Region, 2020-2026; Figure 1 : Distribution of Global Elderly Population, by Age Group and Sex, 2020; Figure 2 : Distribution of Global Elderly Population, by Age Group and Sex, 2050; Figure 3 : Funding for Research in Women’s Health, by Disease Condition/Category, 2014-2016; Figure 4 : Funding for Research in Women’s Health, 2014-2016; Figure 5 : Distribution of Insurance Coverage in the U.S., by Type of Healthcare Provider, 2014; Figure 6 : Global Market for Women’s Health Therapeutics, 2018–2026; Figure 7 : Global Market Shares of Women’s Health Therapeutics, by Disease Area, 2020; Figure 8 : Global Market Shares of Women’s Health Therapeutics, by Disease Area, 2026; Figure 9 : Global Market for Menopause Therapeutics, 2020-2026; Figure 10 : Global Market for Menopause Therapeutics, by Region, 2020-2026; Figure 11 : Rate of Hospitalization for Osteoporosis in Australia, by Age Group, 2015-2016; Figure 12 : Global Market for Postmenopausal Osteoporosis Therapeutics, 2020-2026; Figure 13 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, 2020–2026; Figure 14 : Global Market for Endometriosis Therapeutics, 2018–2026; Figure 15 : Global Market for Endometriosis Therapeutics, by Region, 2020–2026; Figure 16 : Global Market for PCOS Therapeutics, 2018–2026; Figure 17 : Global Market for PCOS Therapeutics, by Region, 2018–2026; Figure 18 : Global Market for Breast Cancer Therapeutics, 2018–2026; Figure 19 : Global Market for Breast Cancer Therapeutics, by Region, 2020–2026; Figure 20 : Global Market for Women’s Health Therapeutics, by Region, 20202026; Figure 21 : North American Market Shares of Women’s Health Therapeutics, by Country, 2020; Figure 22 : North American Market for Women’s Health Therapeutics, 2018–2026; Figure 23 : North American Market Shares of Women’s Health Therapeutics, by Disease Area, 2020; Figure 24 : North American Market for Women’s Health Therapeutics, by Country, 2020–2026; Figure 25 : U.S. Market for Women’s Health Therapeutics, 2018–2026; Figure 26 : Canadian Market for Women’s Health Therapeutics, 2018–2026; Figure 27 : Mexican Market for Women’s Health Therapeutics, 2018–2026; Figure 28 : European Market for Women’s Health Therapeutics, by Country, 2020–2026; Figure 29 : European Market Shares of Women’s Health Therapeutics, by Country, 2020; Figure 30 : European Market for Women’s Health Therapeutics, 2018–2026; Figure 31 : European Market Shares of Women’s Health Therapeutics, by Disease Area, 2020; Figure 32 : U.K. Market for Women’s Health Therapeutics, 2018–2026; Figure 33 : German Market for Women’s Health Therapeutics, 2018–2026; Figure 34 : French Market for Women’s Health Therapeutics, 2018–2026; Figure 35 : Spanish Market for Women’s Health Therapeutics, 2018–2026; Figure 36 : Italian Market for Women’s Health Therapeutics, 2018–2026; Figure 37 : Rest of the European Market for Women’s Health Therapeutics, 2018–2026; Figure 38 : Asia-Pacific Market for Women’s Health Therapeutics, 2018–2026; Figure 39 : Asia-Pacific Market Shares of Women’s Health Therapeutics, by Disease Area, 2020; Figure 40 : Asia-Pacific Market Shares of Women’s Health Therapeutics, by Disease Area, 2020; Figure 41 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, 2020–2026; Figure 42 : Chinese Market for Women’s Health Therapeutics, 2018–2026; Figure 43 : Japanese Market for Women’s Health Therapeutics, 2018–2026; Figure 44 : Indian Market for Women’s Health Therapeutics, 2018–2026; Figure 45 : South Korean Market for Women’s Health Therapeutics, 2018–2026; Figure 46 : Rest of Asia-Pacific Countries’ Market for Women’s Health Therapeutics, 2018–2026; Figure 47 : RoW Market for Women’s Health Therapeutics, by Sub-region, 2018–2026; Figure 48 : RoW Market Shares of Women’s Health Therapeutics, by Subregion, 2020; Figure 49 : RoW Market for Women’s Health Therapeutics, 2018–2026; Figure 50 : RoW Market Shares of Women’s Health Therapeutics, by Disease Area, 2020; Figure 51 : South American Market for Women’s Health Therapeutics, 2018–2026; Figure 52 : South American Market Shares of Women’s Health Therapeutics, by Disease Area, 2020; Figure 53 : Middle East and African Market for Women’s Health Therapeutics, 2018–2026; Figure 54 : Global Market Shares of Women’s Health Therapeutics, by Company, 2020; Figure 55 : AbbVie: Hematologic Oncology Annual Revenue, 2018-2020; Figure 56 : AbbVie Inc.: Revenue Share, by Country, 2020; Figure 57 : Allergan plc: Revenue Share, by Business Segment, 2017; Figure 58 : Amgen Oncology Pharmaceuticals: Annual Revenue, 2018-2020; Figure 59 : AstraZeneca’s Oncology Segment: Annual Revenue, 2018-2020; Figure 60 : Bayer AG: Oncology Pharmaceutical Annual Revenue, 2018-2020; Figure 61 : Bayer AG: Revenue Share, by Region, 2018; Figure 62 : Bayer AG: Revenue Share, by Business Segment, 2018; Figure 63 : Bristol-Myers Squibb Oncology Pharmaceuticals: Annual Revenue, 2018-2020; Figure 64 : Daiichi Sankyo Co. Ltd.: R&D Expenditure, 2014–2016; Figure 65 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018; Figure 66 : Eli Lilly and Co.: Revenue Share, by Business Segment, 2018; Figure 67 : Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020; Figure 68 : Roche: Oncology Annual Revenue, 2018-2020; Figure 69 : Gilead Sciences Inc.: Oncology Pharmaceutical Annual Revenue, 2018-2020; Figure 70 : Johnson & Johnson’s Oncology Segment: Annual Revenue, 2018-2020; Figure 71 : Johnson and Johnson Services Inc.: Revenue Share, by Business Segment, 2018; Figure 72 : Johnson & Johnson Services Inc.: Revenue Share, by Region, 2018; Figure 73 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2018; Figure 74 : Merck & Co. Inc.: Revenue Share, by Region, 2018; Figure 75 : Merck & Co.’s Oncology Pharmaceutical: Annual Revenue, 2018-2020; Figure 76 : Novartis’s Oncology Segment: Annual Revenue, 2018-2020; Figure 77 : Novo Nordisk: Revenue Share, by Region, 2018; Figure 78 : Novo Nordisk: Revenue Share, by Business Segment, 2018; Figure 79 : Pfizer Inc.: Oncology Segment: Annual Revenue, 2018-2020; Figure 80 : Pfizer Inc.: Revenue Share, by Region, 2018; Figure 81 : Pfizer Inc.: Revenue Share, by Business Segment, 2018; Figure 82 : Sanofi: Oncology Pharmaceuticals, Annual Revenue, 2018-2020; Figure 83 : Takeda Pharmaceutical: Oncology Annual Revenue, 2019-2021; Figure 84 : Rate of New Cancer Cases in the U.S., by Age Group, 2018